LivaNova PLC (NASDAQ:LIVN – Get Free Report) has received a consensus rating of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $69.17.
A number of analysts recently weighed in on the stock. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Stifel Nicolaus raised their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th.
Read Our Latest Research Report on LivaNova
Institutional Trading of LivaNova
LivaNova Trading Up 2.3 %
Shares of NASDAQ:LIVN opened at $53.00 on Friday. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of 126.52 and a beta of 1.01. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a 50 day moving average price of $51.40 and a 200 day moving average price of $53.00.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Read More
- Five stocks we like better than LivaNova
- How to Use the MarketBeat Stock Screener
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Stock Market Upgrades: What Are They?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Golden Cross Stocks: Pattern, Examples and Charts
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.